Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ca017-078
Previous Study | Return to List | Next Study

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03661320
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : December 11, 2019
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
A study to evaluate nivolumab + chemotherapy or nivolumab/ BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC)

Condition or disease Intervention/treatment Phase
Bladder Cancer Muscle-Invasive Bladder Cancer BMS-986205 Biological: Nivolumab Drug: BMS-986205 Drug: Gemcitabine Drug: Cisplatin Drug: BMS-986205 Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: partially blinded
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Actual Study Start Date : October 12, 2018
Estimated Primary Completion Date : November 28, 2023
Estimated Study Completion Date : December 30, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer
Drug Information available for: Nivolumab

Arm Intervention/treatment
Active Comparator: Arm A
Chemotherapy alone followed by radical cystectomy
Drug: Gemcitabine
Specified dose on specified day
Other Name: Chemotherapy

Drug: Cisplatin
Specified dose on specified day
Other Name: Chemotherapy

Experimental: Arm B
BMS-986205 Placebo + Nivolumab + Chemotherapy followed by BMS-986205 Placebo + Nivolumab post radical cystectomy
Biological: Nivolumab
Specified dose on specified day
Other Names:
  • Opdivo
  • BMS-936558

Drug: Gemcitabine
Specified dose on specified day
Other Name: Chemotherapy

Drug: Cisplatin
Specified dose on specified day
Other Name: Chemotherapy

Drug: BMS-986205 Placebo
Specified dose on specified day

Experimental: Arm C
BMS-986205 + Nivolumab + Chemotherapy followed by Nivolumab plus BMS-986205 post radical cystectomy
Biological: Nivolumab
Specified dose on specified day
Other Names:
  • Opdivo
  • BMS-936558

Drug: BMS-986205
Specified dose on specified day

Drug: Gemcitabine
Specified dose on specified day
Other Name: Chemotherapy

Drug: Cisplatin
Specified dose on specified day
Other Name: Chemotherapy




Primary Outcome Measures :
  1. Pathological Complete Response (pCR) rate, in all randomized participants [ Time Frame: Approx. 39 months ]
    Comparison of Arm B to Arm A; and Comparison of Arm C to Arm A

  2. Event-Free Survival (EFS), in all randomized participants [ Time Frame: Approx. 57 months ]
    Comparison of Arm B to Arm A; and Comparison of Arm C to Arm A;


Secondary Outcome Measures :
  1. Overall Survival (OS) in all randomized participants [ Time Frame: Approx. 76 months ]
    Comparison of Arm C vs Arm A; and Comparison of Arm B vs Arm A

  2. Incidence of Adverse Events (AE) in all treated participants [ Time Frame: Approx. 76 months ]
  3. Incidence of Serious Adverse Events (SAE) in all treated participants [ Time Frame: Approx. 76 months ]
  4. Incidence of Laboratory abnormalities in all treated participants [ Time Frame: Approx. 76 months ]
  5. Incidence of death in all treated participants [ Time Frame: Approx. 76 months ]
  6. Pathological Complete Response (pCR) rate, in all randomized participants [ Time Frame: Approx. 39 months ]
    Comparison of Arm B v Arm C

  7. Event Free Survival (EFS), in all randomized participants [ Time Frame: Approx. 57 months ]
    Comparison of Arm B v Arm C



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with MIBC, clinical stage T2-T4a, N0 (<10 mm on CT or MRI), M0, diagnosed at TURBT and confirmed by radiographic imaging. Variant histology is acceptable if there is a predominant urothelial component.
  • Participant must be deemed eligible for Radial Cystectomy (RC) by his/her oncologist and/or urologist, and must agree to undergo Radial Cystectomy (RC) after completion of neoadjuvant therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

Exclusion Criteria:

  • Clinical evidence of positive LN (≥ 10 mm in short axis) or metastatic bladder cancer
  • Prior systemic therapy, radiation therapy, or surgery for bladder cancer other than TURBT or biopsies is also not permitted
  • Ineligible to receive cisplatin due to Grade 2 or higher peripheral neuropathy or audiometric hearing loss, or calculated (Cockcroft-Gault formula) GFR or measured (24-hour urine) creatinine clearance (CrCl) < 50 mL/min

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03661320


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

  Show 171 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT03661320     History of Changes
Other Study ID Numbers: CA017-078
2017-004692-31 ( EudraCT Number )
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: December 11, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Gemcitabine
Nivolumab
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological